Fuan Pharmaceutical received the drug registration certificate for "Injectable Benzylpenicillin Sodium"

Fuan Pharmaceutical's wholly-owned subsidiary Qingyutang recently obtained the "Sodium Benzylpenicillin Injection" drug registration certificate issued by the National Medical Products Administration. This drug is mainly used to treat infections caused by penicillinase-producing Staphylococcus, including sepsis, endocarditis, pneumonia, and skin and soft tissue infections. So far, 10 companies have passed the consistency evaluation for this drug

According to the Zhitong Finance APP, Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. ("Qingyutang") recently received a drug registration certificate issued by the National Medical Products Administration, involving the drug: "Sodium Benzylpenicillin for Injection."

The indications for Sodium Benzylpenicillin for Injection are: this product is only suitable for the treatment of infections caused by penicillinase-producing Staphylococcus, including sepsis, endocarditis, pneumonia, and skin and soft tissue infections. It can also be used for mixed infections caused by pyogenic streptococcus or pneumococcus and penicillin-resistant Staphylococcus. According to the data query information platform of the National Medical Products Administration, as of now, this drug has been approved for consistency evaluation or deemed to have passed consistency evaluation by 10 companies (including Qingyutang)